Peri-Transplant Administration of Ruxolitinib (Rux) in Patients with Myelofibrosis (MF) Is Safe and Effective. a Pilot Study

Results from a pilot study demonstrated ruxolitinib to be safe and feasible when given at a maximum dose of 10 mg peri-transplant in patients with myelofibrosis. Cumulative incidence of acute graft-versus-host disease (grade 2-4) was 17% (95% CI, 6%-47%) in the 5-mg arm and 11% (95%, 3%-41%) in the 10-mg arm, with a median of 20 days (range, 19-35) and 45 days (range, 18-93), respectively, to development of the side effect.